A global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. We're committed to developing breakthrough treatments …

Baxalta (Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound' [2]) is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. [1]

Dublin, Ireland – June 3, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today completed its previously announced combination with Baxalta Incorporated (NYSE: BXLT), creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions.

2016年1月12日 · After six months of relentless pursuit, Shire (SHPG) finally announced that it will acquire Baxalta, Inc. (BXLT) for $32 billion. The boards of directors of both companies have agreed to the...

Baxalta and Shire Pharma Canada ULC are now part of Takeda, becoming a global, values-based, R&D-driven biopharmaceutical leader. Takeda is the largest pharmaceutical company in Japan and among the largest worldwide, with operations in more than 80 countries and regions.

2016年1月11日 · Ireland-based Shire on Monday announced a $32 billion stock and cash deal to buy Baxalta, bringing its months-long pursuit of the Illinois-based drug company to a close. Baxalta had previously rejected earlier all-stock offers from Shire. Shire will pay $18.00 plus 0.1482 of its American Depository shares for each Baxalta share.

2016年6月3日 · Shire has completed its $32 billion merger with biotech Baxalta in a move aimed at creating a global leader in rare diseases. Baxalta only spun off from Baxter last summer – and Shire moved...